Vosoritide not checked

BioMarin Pharmaceutical · BMN 111

FollowEvery change as it happens, and a Monday email
Stage
in the US · approved in the EU
Next date
Phase 2 trial completes
Trials
10 active
18 in total · 7 in the EU

What this is

How it works
How it works isn't classified yet
How it’s given
“Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.”In the company’s words, NCT03424018 on ClinicalTrials.gov
Tested for
Achondroplasia (5 trials), Hypochondroplasia (2 trials), Idiopathic Short Stature
Main trialPhase 3
“The intent and design of this Phase 3 study is to assess BMN 111 as a therapeutic option for the treatment of children with Achondroplasia”In the company’s words, NCT03424018 on ClinicalTrials.gov
Other names
BMN 111

Other drugs for Achondroplasia

All 8 drugs for Achondroplasia

Coming up7

Changes4

Last 90 days

Trials18

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting Jun 2031 An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia
Phase 3Enrolling by invitation Oct 2044 Long-Term Extension Study of Vosoritide to Treat Children With Hypochondroplasia
Phase 2/3Recruiting Jun 2029 Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia
Phase 2Recruiting Jun 2026 A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature
Phase 2Active, not recruiting Dec 2027 A Clinical Trial to Evaluate Safety of Vosoritide in At-risk Infants With Achondroplasia
Phase 2Active, not recruiting Dec 2027 A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH)
Phase 2Recruiting 30 Jun 2028 A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months
Phase 2Active, not recruiting May 2038 An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia
Phase 3Completed 30 Oct 2019 A Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia
Phase 3Completed 23 Apr 2026 Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia
Phase 2Completed 2 Oct 2017 A Phase 2 Study of BMN 111 to Evaluate Safety, Tolerability, and Efficacy in Children With Achondroplasia
Phase 2Completed 26 Jan 2022 A Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children With Achondroplasia
Phase 2Terminated 16 Sep 2026 A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment
Phase 1Terminated 14 Jun 2023 Bioequivalence Study to Compare Two Injection Devices for BMN 111 in Healthy Participants
Phase 2Authorised not given A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Vosoritide in Infants and Young Children with Hypochondroplasia, Aged 0 to < 36 Months
Phase 3Ended not given A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vosoritide in Children with Hypochondroplasia
Phase 2Ended not given A Phase 2, Randomized, Multicenter, Study of Vosoritide in Children with Noonan Syndrome with Inadequate Growth During or After Human Growth Hormone Treatment
Phase 3Authorised not given A Phase 3, Open-Label, Long-Term Extension Study to Evaluate the Safety and Efficacy of Vosoritide in Children with Hypochondroplasia
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Vosoritide

Following is part of Solo: you see every change to Vosoritide the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in